How to buy Co-Diagnostics stock | $13.43

Co-Diagnostics, Inc is a diagnostics & research business based in the US. Co-Diagnostics shares (CODX) are listed on the NASDAQ and all prices are listed in US Dollars. Co-Diagnostics employs 39 staff and has a trailing 12-month revenue of around 0.00.

Co-Diagnostics share price

Use our graph to track the performance of CODX stocks over time.

Co-Diagnostics shares at a glance

• Key figures

Information last updated 2021-05-07.

Latest market close	$13.43
52-week range	$7.86 - $29.99
50-day moving average	$9.71
200-day moving average	$11.99
Wall St. target price	$23.00
PE ratio	5.4671
Dividend yield	N/A (0%)
Earnings per share (TTM)	$1.52

Buy Co-Diagnostics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Co-Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Co-Diagnostics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Co-Diagnostics price performance over time

Historical closes compared with the close of $13.43 from 2021-03-11

1 week (2021-05-06)	65.39%
1 month (2021-04-13)	40.78%
3 months (2021-02-12)	-20.95%
6 months (2020-11-13)	-10.35%

1 year (2020-05-13)	-42.66%
2 years (2019-05-13)	1,187.14%
3 years (2018-05-11)	629.89%
5 years (2016-05-09)	N/A

Is Co-Diagnostics under- or over-valued?

Valuing Co-Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Co-Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Co-Diagnostics's P/E ratio

Co-Diagnostics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Co-Diagnostics shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Co-Diagnostics's EBITDA

Co-Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $41.8 million.

The EBITDA is a measure of a Co-Diagnostics's overall financial performance and is widely used to measure a its profitability.

Co-Diagnostics financials

Revenue TTM	$74.6 million
Operating margin TTM	55.93%
Gross profit TTM	$58 million
Return on assets TTM	70.95%
Return on equity TTM	124.15%
Profit margin	56.98%
Book value	$2.34
Market capitalisation	$238.2 million

TTM: trailing 12 months

Shorting Co-Diagnostics shares

There are currently 4.2 million Co-Diagnostics shares held short by investors – that's known as Co-Diagnostics's "short interest". This figure is 14.1% down from 4.9 million last month.

There are a few different ways that this level of interest in shorting Co-Diagnostics shares can be evaluated.

Co-Diagnostics's "short interest ratio" (SIR)

Co-Diagnostics's "short interest ratio" (SIR) is the quantity of Co-Diagnostics shares currently shorted divided by the average quantity of Co-Diagnostics shares traded daily (recently around 1.2 million). Co-Diagnostics's SIR currently stands at 3.51. In other words for every 100,000 Co-Diagnostics shares traded daily on the market, roughly 3510 shares are currently held short.

However Co-Diagnostics's short interest can also be evaluated against the total number of Co-Diagnostics shares, or, against the total number of tradable Co-Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Co-Diagnostics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Co-Diagnostics shares in existence, roughly 150 shares are currently held short) or 0.1482% of the tradable shares (for every 100,000 tradable Co-Diagnostics shares, roughly 148 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Co-Diagnostics.

Find out more about how you can short Co-Diagnostics stock.

Co-Diagnostics share dividends

We're not expecting Co-Diagnostics to pay a dividend over the next 12 months.

Co-Diagnostics share price volatility

Over the last 12 months, Co-Diagnostics's shares have ranged in value from as little as $7.86 up to $29.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Co-Diagnostics's is -1.9768. This would suggest that Co-Diagnostics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Co-Diagnostics has bucked the trend.

Co-Diagnostics overview

Co-Diagnostics, Inc. , a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. .

Frequently asked questions

• What percentage of Co-Diagnostics is owned by insiders or institutions?

  Currently 6.355% of Co-Diagnostics shares are held by insiders and 28.876% by institutions.

• How many people work for Co-Diagnostics?

  Latest data suggests 39 work at Co-Diagnostics.

• When does the fiscal year end for Co-Diagnostics?

  Co-Diagnostics's fiscal year ends in December.

• Where is Co-Diagnostics based?

  Co-Diagnostics's address is: 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109

• What is Co-Diagnostics's ISIN number?

  Co-Diagnostics's international securities identification number is: US1897631057

• What is Co-Diagnostics's CUSIP number?

  Co-Diagnostics's Committee on Uniform Securities Identification Procedures number is: 189763105